[Studies on the fate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207), a carcinostatic agent. III. Absorption, distribution, excretion and metabolism after rectal administration of FT-207 (author's transl)].
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000378:metabolism; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism; D051381:Rats; D013488:Suppositories
D000970:Antineoplastic Agents; D013488:Suppositories; D005472:Fluorouracil